Different focal delayed gadolinium-enhancement patterns using cardiac magnetic resonance in a case of diffuse giant cell myocarditis.

insights from the randomized TAXUS II trial. Circulation 2005;111:900–905. 27. Wieneke H, Dirsch O, Sawitowski T, Gu YL, Brauer H, Dahmen U, Fischer A, Wnendt S, Erbel R. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Catheter Cardiovasc Interv 2003;60: 399–407. 28. Kollum M, Farb A, Schreiber R, Terfera K, Arab A, Geist A, Haberstroh J, Wnendt S, Virmani R, Hehrlein C. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Catheter Cardiovasc Interv 2005;64:85–90. 29. Bartorelli A. Tacrolimus drug-eluting stents. In: The Sorin JANUS FIM Results (JUPITER I) and New Clinical Trial Insights. Washington: TCT; 2004. 30. Morice M-C, Bestehorn H-P, Carrié D, Macaya C, Aengevaeren W, Wijns W, Dubois C, de Winter R, Verheye S, Hoffmann S, Pachinger O, Mario CD. Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus carbon-coated carbostents. The randomized JUPITER II trial. Eurointervention 2006;2:45–52. 31. Dawkins KD. Randomized, multi-center evaluation of the pimecrolimus-eluting and the dual pimecrolimus/paclitaxel-eluting coronary stent system in patients with de novo lesions of the native coronary arteries: GENESIS trial 6 month results. SCAI / ACCi2 2008, Chicago, 2008. 32. Zhang J, Rodila R, Watson P, Ji Q, El-Shourbagy TA. Determination of sirolimus in rabbit arteries using liquid chromatography separation and tandem mass spectrometric detection. Biomed Chromatogr 2007;21:1036–1044. 33. Garcia-Garcia HM, Gonzalo N, Kukreja N, Alfonso F. Greyscale intravascular ultrasound and IVUS-radiofrequency tissue characterisation to improve understanding of the mechanisms of coronary stent thrombosis in drug-eluting stents. Eurointervention 2008;4:C33–C38. 34. Serruys PW, Sianos G, Abizaid A, Aoki J, den Heijer P, Bonnier H, Smits P, McClean D, Verheye S, Belardi J, Condado J, Pieper M, Gambone L, Bressers M, Symons J, Sousa E, Litvack F. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 2005;46:253–260. 35. Aoki J, Colombo A, Dudek D, Banning AP, Drzewiecki J, Zmudka K, Schiele F, Russell ME, Koglin J, Serruys PW. Peristent remodeling and neointimal suppression 2 years after polymer-based, paclitaxel-eluting stent implantation: insights from serial intravascular ultrasound analysis in the TAXUS II study. Circulation 2005;112:3876–3883. 36. Degertekin M, Lemos PA, Lee CH, Tanabe K, Sousa JE, Abizaid A, Regar E, Sianos G, van der Giessen WJ, de Feyter PJ, Wuelfert E, Popma JJ, Serruys PW. Intravascular ultrasound evaluation after sirolimus eluting stent implantation for de novo and in-stent restenosis lesions. Eur Heart J 2004;25:32–38.